Cosibelimab

Programmed cell death-ligand 1 (PD-L1) is an immune checkpoint regulator: It is expressed on various cells to interact with its receptors to suppress the immune response. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation, and cytokine production. PD-L1 is often overexpressed on cutaneous squamous cell carcinoma (CSCC) tumour cells and tumour-infiltrating immune cells. PD-L1 can contribute to the inhibition of the anti-tumour immune response in the tumour microenvironment, promoting tumour immune evasion and dysregulated tumour growth.

Cosibelimab is a high-affinity PD-L1-blocking antibody. It blocks the interaction between PD-L1 and its receptors PD-1 and B7.1, thereby releasing the inhibitory effects of PD-L1 on the anti-tumour immune response. Cosibelimab activates innate and adaptive immunity.